CClinicalTrials.gg
CompletedNCT00068874Updated May 9, 2018

Improving Quality of Life for African American Female Adolescents With Lupus

A Phase 2 interventional study of Coping skills and cognitive restructuring techniques and Educational training in Lupus, sponsored by Medical University of South Carolina. Completed at 1 site in United States. Open to female participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-05-09.

Sponsored by Medical University of South Carolina · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
Female
01

Study summary

This study will evaluate a program designed to help African American adolescents with lupus (systemic lupus erythematosus or SLE) cope with the disease.

Read the detailed description

SLE is the most common autoimmune connective tissue disease of childhood, affecting 5,000 to 10,000 children; the prevalence is higher among African American children and approximately 80% of sufferers are female. SLE is multisystemic in onset and has no known cure. Children with chronic illness have at least a two-fold increased risk for adjustment problems relative to their healthy peers. This risk is heightened among adolescents, who are at greater risk for psychopathology than are younger children. The diagnosis of a chronic medical condition during adolescence presents unique stressors, particularly for adolescents with lupus, who must endure bodily changes, including dermatological problems, hair loss, and changes in appearance due to medical therapies. Psychosocial processes, including methods of coping, expectations, and family functioning, are believed to mediate the influence of disease severity. This study will evaluate the effectiveness of a cognitive-based intervention to improve the quality of life of adolescents with SLE.

Participants in this study will be randomly assigned to either the cognitive-based intervention, a lupus education program, or a control group. Participants in the intervention group will have five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses. Caregivers will join the adolescent at the end of each training session to gain familiarity with the content reviewed in each session. The remaining two study visits are booster sessions during which the intervention material will be reviewed.

Participants in the education program will also have five study visits. Study visits will include disease-appropriate education materials. Caregivers will not be included in the education program. Participants will be assessed at study entry and Months 6, 9, and 12. Assessments will include questionnaires designed to measure disease severity, pain intensity, methods of coping, expectations of efficacy, social support, and adjustment.

02

Conditions studied

  • Lupus

Keywords

  • African American
  • Adolescent
  • Coping
  • Adjustment
  • Quality of Life
03

In context

Lead sponsor

Medical University of South Carolina is the lead sponsor of 852 studies on the registry; 165 are open to participants now.

Of its 128 completed or terminated interventional studies of FDA-regulated products, 101 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of systemic lupus erythematosus (SLE)

Exclusion criteria

Exclusion Criteria:

  • Severe depression with suicidal thoughts
  • Delirium, dementia, or cognitive impairment (e.g., Mini Mental Status Examination 24 or less)
  • Severe intellectual impairment
  • Terminal illness with a life expectancy of less than 1 year
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    1

    Educational comparison group

    Behavioral: Educational training

  • Experimental
    2

    Group receiving coping intervention designed to enhance coping and psychological adjustment

    Behavioral: Coping skills and cognitive restructuring techniques

  • No intervention
    3

    Comparison control group with no active intervention

Interventions

  • BehavioralCoping skills and cognitive restructuring techniques

    This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.

    Also known as: HELP - Health Education for Lupus Patients

  • BehavioralEducational training

    Participants will attend five study visits that will include disease-appropriate education materials.

06

What researchers measure

Primary outcomes

  1. BASC scores (measures of general adjustment)

    Time frame: 4 years

  2. BASS Scores

    Time frame: 4 years

  3. SPPA scores (perception of physical appearance and social

    Time frame: 4 years

  4. competence)

    Time frame: 4 years

  5. Peds-QL 4.0 and 3.0 (quality of life assessments)

    Time frame: 4 years

  6. Psychological Adjustment

    Time frame: 4 years

  7. BASC Scores

    Time frame: 4 years

Secondary outcomes

  1. SLEDAI (measure of disease status)

    Time frame: 4 years

07

Study locations

1 site
  • Ronald T. Brown, PhD
    Philadelphia, Pennsylvania 19140, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00068874
Lead sponsor
Medical University of South Carolina
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted
Sep 11, 2003
Start date
Apr 2004
Primary completion
Apr 2007
Completion
Apr 2007
Last update
May 9, 2018

Study contacts

Ronald T. Brown, PhD
principal investigator · Department of Public Health - Temple University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion